Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Medical Unit Head-Neck-Lung-Skin Cancer, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
Lung Cancer. 2024 Jun;192:107826. doi: 10.1016/j.lungcan.2024.107826. Epub 2024 May 22.
The aim of this study was to evaluate if the previously reported improvements in lung cancer survival were consistent across age at diagnosis and by lung cancer subtypes.
Data on lung cancers diagnosed between 1990 and 2016 in Denmark, Finland, Iceland, Norway and Sweden were obtained from the NORDCAN database. Flexible parametric models were used to estimate age-standardized and age-specific relative survival by sex, as well as reference-adjusted crude probabilities of death and life-years lost. Age-standardised survival was also estimated by the three major subtypes; adenocarcincoma, squamous cell and small-cell carcinoma.
Both 1- and 5-year relative survival improved continuously in all countries. The pattern of improvement was similar across age groups and by subtype. The largest improvements in survival were seen in Denmark, while improvements were comparatively smaller in Finland. In the most recent period, age-standardised estimates of 5-year relative survival ranged from 13% to 26% and the 5-year crude probability of death due to lung cancer ranged from 73% to 85%. Across all Nordic countries, survival decreased with age, and was lower in men and for small-cell carcinoma.
Lung cancer survival has improved substantially since 1990, in both women and men and across age. The improvements were seen in all major subtypes. However, lung cancer survival remains poor, with three out of four patients dying from their lung cancer within five years of diagnosis.
本研究旨在评估在诊断时的年龄和肺癌亚型方面,之前报告的肺癌生存率的改善是否具有一致性。
从 NORDCAN 数据库中获取了丹麦、芬兰、冰岛、挪威和瑞典在 1990 年至 2016 年间诊断的肺癌数据。使用灵活的参数模型来估计按性别、参考调整的粗死亡率和生命损失年数的年龄标准化和年龄特异性相对生存率。还按三大主要亚型(腺癌、鳞状细胞癌和小细胞癌)估计了年龄标准化的生存率。
所有国家的 1 年和 5 年相对生存率均持续提高。改善的模式在各年龄组和亚型之间相似。在丹麦,生存的改善最大,而在芬兰,改善相对较小。在最近的时期,5 年相对生存率的年龄标准化估计值范围为 13%至 26%,肺癌导致的 5 年粗死亡率范围为 73%至 85%。在所有北欧国家中,生存率随年龄下降,男性和小细胞癌的生存率较低。
自 1990 年以来,女性和男性以及各年龄段的肺癌生存率都有了显著提高。所有主要亚型都有改善。然而,肺癌的生存率仍然很差,四分之三的患者在诊断后五年内死于肺癌。